HeartBeam adds duo of medtech veterans to its board
08 Jun 2023
Executive Change
HeartBeam (Nasdaq:BEAT) announced today that it appointed Ken Nelson and Mark Strome to its board of directors.
The appointment of Nelson and Strome became effective on June 5, 2023. HeartBeam develops a proprietary 3D-vector ECG platform intended for patient use at home.
Nelson, 48, brings with him 20 years of experience in digital health, medical devices and remote patient monitoring. Over the past decade, he led commercial efforts for companies including BioTelemetry, iRhythm and Bardy Diagnostics. Most recently, he served as head of digital health, diagnostics and monitoring for Biotronic. Nelson currently chairs the CardiaCare board and serves as an active board member for a handful of other startups.
Strome, 66, offers HeartBeam more than 40 years of experience in investment management and securities. He serves as founder, chief investment officer and chair at Strome Investment Management and Strome Group. Previously, Strome served as portfolio manager at Kayne Anderson.
Additionally, Strome had involvement in the founding and incubation of companies including Pulse Biosciences and iWood Studios.
“We are privileged to welcome two members with highly relevant backgrounds to HeartBeam’s board,” said Branislav Vajdic, HeartBeam CEO and founder. “Ken brings extensive experience and insights in cardiac digital health, remote patient monitoring, and medical devices. His firsthand knowledge of our industry will be a critical resource as we progress on our corporate goals. Mark is an experienced investor and business executive who will help us expand the breadth and depth of our reach as a company, positioning us to create additional value for our shareholders.
“Together, Ken and Mark will contribute a wealth of expertise to the board, adding to the exceptional team that we have elected to guide us forward and commercialize our business.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.